How should I use Breztri Aerosphere (beclomethasone dipropionate, formoterol fumarate, glycopyrronium bromide) as a twice‑daily maintenance inhaler for an adult with asthma or COPD?

Breztri Aerosphere: Dosing and Administration

Breztri Aerosphere should be administered as 2 inhalations twice daily (morning and evening) for maintenance treatment of COPD in adults. 1

Approved Indication

Breztri Aerosphere is a triple-combination inhaler containing budesonide (ICS) 160 mcg, glycopyrronium (LAMA) 9 mcg, and formoterol fumarate (LABA) 4.8 mcg per inhalation. 1 It is FDA-approved exclusively for maintenance treatment of chronic obstructive pulmonary disease (COPD) and is NOT indicated for asthma treatment. 1

Dosing Regimen

• Standard dose: 2 inhalations twice daily (total daily dose: budesonide 640 mcg, glycopyrronium 36 mcg, formoterol 19.2 mcg)
• Administer via oral inhalation using the pressurized metered-dose inhaler (pMDI)
• Timing: One dose in the morning, one dose in the evening, approximately 12 hours apart

Clinical Context and Evidence Base

The recommendation for triple therapy in COPD is strongly supported by recent high-quality evidence. For patients with moderate to severe COPD at high risk of exacerbations (≥2 moderate exacerbations or ≥1 severe exacerbation in the past year), triple LAMA/LABA/ICS combination therapy is superior to dual therapy and reduces mortality. 2

The 2023 Canadian Thoracic Society guideline provides the most current evidence, demonstrating that triple therapy with LAMA/LABA/ICS significantly reduces all-cause mortality compared to LAMA/LABA dual therapy (hazard ratios 0.54-0.64 in major trials), while also preventing exacerbations and improving symptoms. 2 This mortality benefit represents a critical advancement in COPD management.

Who Should Receive Breztri

Triple therapy is indicated for patients with:

• High exacerbation risk: ≥2 moderate COPD exacerbations or ≥1 hospitalization for COPD in the past year
• High symptom burden: mMRC ≥2 or CAT score ≥10
• Moderate to severe airflow limitation: FEV₁ <80% predicted
• Inadequate control on dual bronchodilator therapy (LAMA/LABA) or ICS/LABA combinations

2

Comparison to Other Regimens

The 2015 CHEST/CTS guidelines established that combination ICS/LABA therapy reduces exacerbations compared to LABA monotherapy (Grade 1C), and that triple therapy (LAMA/ICS/LABA) is appropriate for severe COPD. 3 However, the 2023 guideline strengthens this recommendation based on mortality data, making triple therapy the preferred option for high-risk patients rather than a stepwise escalation. 2

Critical Safety Considerations

Absolute Contraindications

• Do NOT use for acute symptom relief or rescue therapy 1
• Do NOT initiate during acute COPD exacerbations 1
• Do NOT use in asthma - LABA monotherapy increases asthma-related deaths; while Breztri contains an ICS, it is not approved for asthma and should not be used 1
• Hypersensitivity to budesonide, glycopyrronium, formoterol, or excipients 1

Do NOT Combine With:

• Other LABA-containing medications (salmeterol, vilanterol, olodaterol, indacaterol) - risk of LABA overdose 1
• Other anticholinergics (tiotropium, ipratropium, aclidinium, umeclidinium) - risk of anticholinergic toxicity 1

Important Warnings

Pneumonia risk: ICS-containing regimens increase pneumonia risk by approximately 4% in COPD patients. 4 Monitor for signs/symptoms of pneumonia (fever, increased sputum production, change in sputum color, increased cough).

Immunosuppression: Corticosteroids increase infection susceptibility. Use caution in patients with active or quiescent tuberculosis, fungal infections, or viral infections. 1

Cardiovascular effects: Beta-agonists can cause tachycardia, arrhythmias, hypertension, and QT prolongation. Use cautiously in patients with cardiovascular disease. 1

Urinary retention: Anticholinergics worsen urinary retention. Use cautiously in prostatic hyperplasia or bladder-neck obstruction; instruct patients to report difficulty urinating immediately. 1

Narrow-angle glaucoma: May precipitate acute angle-closure glaucoma. Patients should report eye pain, blurred vision, or visual halos immediately. 1

Paradoxical bronchospasm: If acute bronchospasm occurs after dosing, discontinue immediately and use rescue inhaler. 1

Adrenal suppression: When switching from systemic corticosteroids, taper slowly to avoid adrenal crisis. High-dose or prolonged ICS use may cause hypercorticism and adrenal suppression. 1

Bone mineral density: Long-term ICS use decreases bone density; assess BMD in high-risk patients. 1

Patient Instructions

• Always have a rescue inhaler (short-acting bronchodilator like albuterol) available for acute symptoms 1
• Rinse mouth with water after each use without swallowing to reduce oral candidiasis risk 1
• Do not increase dose or frequency without physician guidance
• Prime inhaler before first use or if not used for >7 days
• Clean actuator weekly with dry cloth only
• Discard after labeled number of actuations even if canister not empty

Drug Interactions

Strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole): Increase systemic corticosteroid exposure; use with caution and monitor for Cushing's syndrome. 1

Other adrenergic drugs: May potentiate cardiovascular effects of formoterol. 1

Diuretics, xanthines, systemic steroids: May potentiate hypokalemia; monitor potassium levels. 1

Real-World Effectiveness

Recent observational data from over 5,000 European COPD patients showed that BDP/formoterol/glycopyrronium triple therapy significantly improved CAT scores (mean reduction -3.8 to -4.7 points), reduced exacerbation rates from 93.1% to 35.7%, improved FEV₁ by ≥100 mL in >40% of patients, and enhanced medication adherence over 6-12 months. 5 These real-world outcomes support the efficacy demonstrated in clinical trials.